Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.27 USD
+0.10 (1.22%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $8.46 +0.19 (2.30%) 6:52 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATRA 8.27 +0.10(1.22%)
Will ATRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATRA
All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
Other News for ATRA
Biotech Alert: Searches spiking for these stocks today
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel?) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Atara announces $20M milestone from Pierre Fabre amid filing of tab-cel BLA
Atara lead asset tab-cel undergoes FDA priority review